DEXYCU KIT

Peak

dexamethasone

NDAINTRAOCULARSUSPENSION

Approved

Feb 2018

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Indications (2)

postoperative inflammation postoperative inflammation ( )

Clinical Trials (5)

NCT07175415Phase 1/2Not Yet Recruiting

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Started Oct 2026

42 enrolled

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory+2 more

NCT07479979Phase 1/2Not Yet Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Started Jul 2026

62 enrolled

Relapse Multiple MyelomaRefractory Multiple Myeloma

NCT07285239Phase 3Not Yet Recruiting

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Started May 2026

500 enrolled

Multiple Myeloma

NCT07224672Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Started Mar 2026

60 enrolled

Amyloidosis

NCT07348393Phase 2Not Yet Recruiting

A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Started Feb 2026

70 enrolled

Relapsed or Refractory Multiple Myeloma (RRMM)